Product Name:5-(4-Bromophenyl)-4,6-dichloropyrimidine

IUPAC Name:5-(4-bromophenyl)-4,6-dichloropyrimidine

CAS:146533-41-7
Molecular Formula:C10H5BrCl2N2
Purity:95%+
Catalog Number:CM166576
Molecular Weight:303.97

Packing Unit Available Stock Price($) Quantity
CM166576-25g in stock ǟǎŮ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:146533-41-7
Molecular Formula:C10H5BrCl2N2
Melting Point:-
Smiles Code:ClC1=C(C2=CC=C(Br)C=C2)C(Cl)=NC=N1
Density:
Catalog Number:CM166576
Molecular Weight:303.97
Boiling Point:368.7±42.0°C at 760 mmHg
MDL No:MFCD13151897
Storage:Keep in a dry and a tight container and store at ambient temperature

Category Infos

Pyrimidines
Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.
Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Aprocitentan
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023.
Aprocitentan is an investigational, novel, oral, dual endothelin receptor antagonist (ERA), which potently inhibits the binding of ET-1 to ETA and ETB receptors. Aprocitentan has a low potential for drug-drug interaction and a mechanism of action that is ideally suited for the pathophysiology of resistant hypertension.
A new drug application (NDA) for aprocitentan was accepted for review by the US FDA.

Related Products